Back to Results

Zoster Eye Disease Study (ZEDS)


Title Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus
Therapeutic Area Herpes Zoster
Principal Investigator Kenneth Kenyon, MD
Min Age 18 Years
Gender Any
Contact Carly Satsuma
617-636-5489
neecresearch@tuftsmedicalcenter.org
More Information https://clinicaltrials.gov/ct2/show/NCT03134196

Overview

This study is a double-masked, placebo controlled randomized clinical trial looking to find out whether one year of a low dose of the medicine valacyclovir reduces complications of shingles affecting the eye.

Study Details

Inclusion Criteria

  • Ability to take oral medication and willing to adhere to study medication regimen
  • Diagnosed with Herpes Zoster Ophthalmicus (HZO) in one eye with V1 distribution and documented history within 1 year of enrollment of either dendritiform epithelial keratitis (DEK), stromal keratitis (SK), endothelial keratitis (EK), or iritis (IR

Exclusion Criteria

  • History of immunocompromised status
  • Renal insufficiency
  • Allergy or adverse reaction to valcyclovir or acyclovi

Study Requirements

8 study visits over the span of 18-21 months. 5 blood collections of approximately 2 teaspoons each time.